CA3190461A1 - Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same - Google Patents

Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same

Info

Publication number
CA3190461A1
CA3190461A1 CA3190461A CA3190461A CA3190461A1 CA 3190461 A1 CA3190461 A1 CA 3190461A1 CA 3190461 A CA3190461 A CA 3190461A CA 3190461 A CA3190461 A CA 3190461A CA 3190461 A1 CA3190461 A1 CA 3190461A1
Authority
CA
Canada
Prior art keywords
compound
pyrimidin
benzamide
pyridin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3190461A
Other languages
English (en)
French (fr)
Inventor
Young Jun Park
Sung Jun Park
Hyebin YOO
Hyunnam SONG
Si-Eun YUN
Sojin Park
Joon Woo Kim
Sung Il Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axceso Biopharma Co Ltd
Original Assignee
Axceso Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axceso Biopharma Co Ltd filed Critical Axceso Biopharma Co Ltd
Publication of CA3190461A1 publication Critical patent/CA3190461A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3190461A 2020-09-16 2021-09-15 Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same Pending CA3190461A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200119100 2020-09-16
KR10-2020-0119100 2020-09-16
PCT/KR2021/012616 WO2022060094A1 (ko) 2020-09-16 2021-09-15 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물

Publications (1)

Publication Number Publication Date
CA3190461A1 true CA3190461A1 (en) 2022-03-24

Family

ID=80777269

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3190461A Pending CA3190461A1 (en) 2020-09-16 2021-09-15 Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same

Country Status (11)

Country Link
US (1) US12590098B2 (https=)
EP (1) EP4215533B1 (https=)
JP (1) JP7824667B2 (https=)
KR (1) KR102673031B1 (https=)
CN (1) CN116137815B (https=)
AU (1) AU2021344164A1 (https=)
BR (1) BR112023004179A2 (https=)
CA (1) CA3190461A1 (https=)
IL (1) IL300920A (https=)
MX (1) MX2023003087A (https=)
WO (1) WO2022060094A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001098A (es) * 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
BRPI0514738A (pt) 2004-08-31 2008-06-24 Hoffmann La Roche derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
UY29439A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
RU2007147917A (ru) * 2005-06-10 2009-07-20 Айрм Ллк (Bm) Соединения, поддерживающие плюрипотентность эмбриональных стволовых клеток
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
GB201315072D0 (en) 2013-08-23 2013-10-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders
AU2017291812B2 (en) * 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
KR102591947B1 (ko) * 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
KR102382613B1 (ko) * 2020-01-15 2022-04-06 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물

Also Published As

Publication number Publication date
EP4215533B1 (en) 2026-02-11
CN116137815A (zh) 2023-05-19
BR112023004179A2 (pt) 2023-04-11
US20230348474A1 (en) 2023-11-02
JP7824667B2 (ja) 2026-03-05
KR20220036895A (ko) 2022-03-23
EP4215533A4 (en) 2024-12-18
IL300920A (en) 2023-04-01
WO2022060094A1 (ko) 2022-03-24
JP2023541052A (ja) 2023-09-27
CN116137815B (zh) 2025-08-19
KR102673031B1 (ko) 2024-06-07
MX2023003087A (es) 2023-04-14
AU2021344164A9 (en) 2024-03-21
AU2021344164A1 (en) 2023-05-04
US12590098B2 (en) 2026-03-31
EP4215533A1 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
US11459340B2 (en) Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
TWI385165B (zh) 經二取代之呔猬狀途徑拮抗劑
CN103502217B (zh) 包含酪氨酸激酶抑制剂的二芳基乙炔酰肼
US7790756B2 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US7897762B2 (en) Kinase inhibitors useful for the treatment of proliferative diseases
US20120329796A1 (en) Compounds useful for treating premature aging and in particular progeria
EP3388428A1 (en) Five-membered heterocyclic amides wnt pathway inhibitor
TWI810520B (zh) 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
US20210395242A1 (en) Heterocyclic compounds as ahr modulators
US12312337B2 (en) Compounds and methods for treating cancer
US20210315869A1 (en) Compounds and methods for csk modulation and indications therefor
US20240228491A1 (en) Methionine adenosyltransferase inhibitor, preparation method therefor and application thereof
US20250376445A1 (en) Compounds and methods for yap/tead modulation and indications therefor
US20110166144A1 (en) Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same
KR102673031B1 (ko) 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물
TWI546304B (zh) Protein tyrosine kinase inhibitors and their use
RS53749B1 (sr) Derivati 4-(metilaminofenoksi)pirdin-3-il-benzamida za lečenje kancera
US12565491B2 (en) (Isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof
WO2020004518A1 (ja) 新規ｐｄｅ４阻害剤
US20250221979A1 (en) Novel heterocyclic compound
US20250376458A1 (en) Compounds and methods for yap/tead modulation and indications therefor
WO2025255343A1 (en) Pyrrolopyrimidine inhibitors of wild-type and mutant lrrk2
HK40095524A (zh) 吡唑酰胺衍生物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240903

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240903

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240903

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250822

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250822

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250829

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250829

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250829

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251105

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251105

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251107